Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fluorouracil,Calcipotriol
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SKNV Launches Kefunova, a Custom Formulated 5-FU Prescription Medication
Details : Kefunova Cream (Fluorouracil/Calcipotriene), a new topical therapy developed in direct response to the needs of dermatology providers treating actinic keratosis & superficial basal cell carcinoma.
Product Name : Kefunova
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 30, 2025
Lead Product(s) : Fluorouracil,Calcipotriol
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Endo Pharm
Deal Size : Undisclosed
Deal Type : Agreement
Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada
Details : The agreement aims to commercialize Wynzora Cream, a combination of calcipotriene and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis, in Canada.
Product Name : Wynzora
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 15, 2024
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Endo Pharm
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
LEO Pharma Submits NDA For Enstilar® For Psoriasis Treatment in China
Details : Enstilar is a combination of calcipotriene hydrate as a synthetic vitamin D3 analog and betamethasone dipropionate as a synthetic corticosteroid, indicated as topical treatment of plaque psoriasis.
Product Name : Enstilar
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 27, 2024
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Hyphens Pharma
Deal Size : $2.7 million
Deal Type : Licensing Agreement
Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics
Details : MC2 gains commercialization rights for Wynzora, an approved product indicated for treating plaque psoriasis in patients 18 years and older, through a license agreement.
Product Name : Wynzora
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 12, 2024
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Hyphens Pharma
Deal Size : $2.7 million
Deal Type : Licensing Agreement
Lead Product(s) : Calcipotriol
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Effect of Topical Calcipotriol Versus Platelet-Rich Plasma
Details : Calcipotriol is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Alopecia Areata.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 20, 2023
Lead Product(s) : Calcipotriol
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The product is the combination of calcipotriene hydrate as a synthetic vitamin D3 analog and betamethasone dipropionate as a synthetic corticosteroid. It is indicated for the topical treatment of plaque psoriasis.
Product Name : Enstilar-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 23, 2023
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : MC2 Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : WYNZORA is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis. It is based on PAD™ Technology, which enables stability of both calcipotriene and betamethasone dipropionate in a...
Product Name : Wynzora
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 15, 2022
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : MC2 Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcipotriol
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Bioskin
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Akvano (Calcipotriol) is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Psoriasis.
Product Name : Akvano
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 05, 2022
Lead Product(s) : Calcipotriol
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Bioskin
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Positive results from the Phase III study with Lipidor’s drug candidate AKP02, which is based on calcipotriol alone & in combination with betamethasone, show that AKVANO® technology works well for drugs for treatment of psoriasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 20, 2022
Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcipotriol
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase III Study in Subjects With Mild to Moderate Psoriasis.
Details : Calcipotriol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 22, 2022
Lead Product(s) : Calcipotriol
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable